Haptic patch cut pain and improved mobility in 118-person trial

A drug-free wearable patch reduced pain and improved range of motion versus placebo in a randomized study of 118 adults presented at Business of Pain 2026 in Miami Beach. The results point to a non-drug option for people with myofascial, musculoskeletal, arthritic and neuropathic pain.

Why it matters: - The findings add to evidence that a non-drug wearable may help people manage pain without medication side effects. - The study reported both pain relief and mobility gains over 14 days, which matters for patients whose pain limits daily movement. - No adverse events were reported, which strengthens the case for further study of the patch as a low-risk option.

What happened: - Clarity Science, LLC presented randomized, double-blind trial results on Oct. 8, 2026 at the Business of Pain 2026 meeting at the Fontainebleau Miami Beach in Miami Beach, Florida. - The study compared the FREEDOM haptic patch with a similar-looking placebo patch in 118 adults. - Participants had myofascial, musculoskeletal, arthritic or neuropathic pain. - The patch was placed near the source of pain and replaced daily for 14 days. - All 118 participants completed the study.

The details: - The active group included 64 participants; the placebo group included 54. - Pain was measured with the validated Brief Pain Inventory. - Range of motion was measured with the Schober test, goniometer and inclinometer. - Pain severity and pain interference improved more with the active patch than with placebo at Day 14, with P=.001 and P=.012. - Median pain severity in the active group fell by 2.75 points on the 0-10 Brief Pain Inventory scale. - Range of motion and flexibility improved more with the active patch than with placebo at Day 7 and Day 14. - The inclinometer result reached P<.001 and the goniometer result reached P=.009. - In participants with low-back pain, the Schober test improved 2.17 cm more with the active patch than with placebo, with P=.0015. - By Day 14, 92% of active-patch users reported pain relief within 20 minutes of application. - By Day 14, 95% of active-patch users reported using less oral pain medication. - By Day 14, 94% of active-patch users were extremely satisfied with the patch, compared with 56% satisfaction in the placebo group. - No adverse events were reported in either group. - The presentation was titled “Reducing Pain Severity and Improving Range of Motion with a Vibrotactile Haptic Patch: Results of a Randomized, Controlled Study.” - Jeffrey Gudin, MD, of the University of Miami Miller School of Medicine, and Peter Hurwitz, president of Clarity Science, authored the presentation.

Between the lines: - The results suggest the patch’s effect is not limited to perceived pain, because mobility measures also improved. - The placebo-controlled design and daily use protocol make the findings more relevant than anecdotal reports, though the study is still relatively small. - The technology is designed to stimulate mechanoreceptors in the skin and engage PIEZO1 and PIEZO2 mechanosensitive ion channels. - The study authors said that signaling is theorized to disrupt the pain neuromatrix, the brain network that shapes pain perception. - The study was funded by SRYSTY Holding Co./The Super Patch Company, the patch manufacturer. - Clarity Science conducted the trial under independent IRB oversight from Advarra.

What's next: - The company and researchers may use the results to support larger studies and broader clinical evaluation of the patch. - Further research will be needed to confirm durability, compare the patch with standard treatments and define which pain conditions benefit most. - The patch is from The Super Patch Company, a Toronto-based wellness technology company that develops drug-free, non-invasive wearable patches using Haptic Vibrotactile Transduction/Trigger Technology. - More information is available in the published source and on the company's website.

The bottom line: - A 14-day randomized trial found that a drug-free haptic patch beat placebo for pain relief and mobility, with no reported adverse events.